Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > R107 Attention !!!

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Oct 02, 2021 2:53pm

198 Views

Post# 33957734

R107 Attention !!!

Hey E....Merck I believe had been working on this and at the 2nd phase their results showed 50% decrease in hospitalization ...so they at that point requested emergency use due to the fact that all results showed it had great potential to save lives ...glta

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?